BREVITY trial

Chief investigator - Professor John Radford, University of Manchester and the Christie NHS Foundation Trust
Cancer type - Hodgkin lymphoma
A phase II study of brentuximab vedotin (SGN-35) using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity
Award start date: 01 Apr 2012
Recruitment start date: 01 Feb 2014
Award duration: 5 years (60 months)

People with Hodgkin lymphoma are usually treated with chemotherapy, but some are too frail to have this type of treatment, or have another medical condition which means they cannot have chemotherapy.

Brentuximab is a type of biological therapy called a monoclonal antibody. It can seek out cancer cells by looking for a molecule called CD30 that is found on the surface of Hodgkin lymphoma cells. Brentuximab vedotin has an additional link to a chemotherapy drug called monomethyl auristatin E. This means that the brentuximab monoclonal antibody can deliver the chemotherapy accurately to the Hodgkin lymphoma cell, causing the cell to die.

Brentuximab vedotin has been shown to be effective for people whose Hodgkin lymphoma has come back after chemotherapy treatment, and researchers want to see if this drug may also help people who can’t have standard chemotherapy. Because brentuximab vedotin is a targeted therapy, it may also have less side effects than chemotherapy.

The aims of this trial were to:

  • Find out if brentuximab vedotin could work as a first treatment for Hodgkin lymphoma
  • Find out more about the side effects

This trial is closed for recruitment, and we hope to update you with the results soon.